Related Experiment Videos
Low dose mitomycin-C in severe vernal keratoconjunctivitis: a randomized prospective double blind study
Arun K Jain1, Jaspreet Sukhija
1Department of Ophthalmology, Post Graduate institute of Medical Education and Research, (PGIMER), Chandigarh, India. arooonjain@hotmail.com
Indian Journal of Ophthalmology
|June 14, 2006
Summary
Low-dose topical Mitomycin C (MMC) effectively and safely treats severe Vernal Keratoconjunctivitis (VKC) exacerbations. This treatment offers significant symptom relief for patients unresponsive to standard therapies.
Area of Science:
- Ophthalmology
- Clinical Pharmacology
Background:
- Vernal Keratoconjunctivitis (VKC) is a severe allergic eye condition.
- VKC can lead to significant ocular discomfort and visual impairment.
- Patients with severe VKC often exhibit resistance to conventional treatments.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose topical Mitomycin C (MMC) for severe VKC.
- To assess MMC's impact on the signs and symptoms of VKC.
Main Methods:
- A placebo-controlled, double-masked, randomized clinical trial was conducted.
- Twenty-eight severe VKC patients received either 0.01% topical MMC or distilled water (placebo) thrice daily for two weeks.
- Signs and symptoms were assessed at baseline and after two weeks, analyzed using the Mann Whitney test.
Main Results:
- No significant difference in symptom severity was noted at presentation between groups.
- The MMC group demonstrated significant reductions in tearing, foreign body sensation, discharge, hyperemia, punctate keratitis, limbal edema, and Trantas spots after two weeks.
- No adverse effects were reported with topical MMC use.
Conclusions:
- Short-term, low-dose topical MMC is a safe and effective treatment for acute exacerbations of severe VKC.
- MMC provides a valuable therapeutic option for VKC patients refractory to conventional treatments.